… Phase I study evaluating the effect of injection speed, volume, and tolerance in healthy
participants suggested that the abdomen is the preferred site for subcutaneous injections 11 and …

… , but current infusion systems require invasive surgery. Subcutaneous infusion of (SC) …
impractical to deliver as a subcutaneous infusion therapy due to skin tolerability. Rather, ND0612 …

… a first-in-human study evaluating the safety, tolerability, and pharmacokinetics (PK) of
ascending single dose levels of TRV250 administered subcutaneously (SC), as well as the relative …

… is intended for 24-h daily continuous subcutaneous infusion (CSCI) [5]. … delivered via a
portable infusion pump through a nasojejunal … Safety and tolerability evaluations were conducted …

… continuous subcutaneous infusion of apomorphine primarily related to potentially troublesome
skin lesions and also the need for an infusion system. … , tolerability, and pharmacokinetics …

… have different efficacy profiles and pharmacokinetic and pharmacodynamic properties, some
of … review provides an overview of the current knowledge on the efficacy and tolerability of …

… prodrugs, the continuous subcutaneous infusion (CSCI) of … by CSCI via an infusion pump
for 72 consecutive hours. Each … tolerability was assessed using the Infusion Site Evaluation …

… In this study we evaluated the safety, tolerability, and pharmacokinetics (PK) profile of
casimersen compared with placebo in participants with exon 45 skip–amenable DMD. …

… levodopa solubility, current infusion systems must be routed … allow assessment of safety,
tolerability, and pharmacokinetics … ), continuous SC administration of ND0612 ameliorated both …

… Two phase 1a, randomized, double-blind placebo-controlled, single-ascending-dose …
subjects to evaluate the safety and pharmacokinetics of ELX-02. Single subcutaneously injected …